iTeos Therapeutics

iTeos Therapeutics operates as a clinical-stage biopharmaceutical company. The Company discovers and develops immuno-oncology therapeutics for treatment of patients. iTeos Therapeutics serves customers in the United States and Belgium.
iTeos Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

iTeos Therapeutics balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

iTeos Therapeutics cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

iTeos Therapeutics multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

iTeos Therapeutics profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
iTeos Therapeutics assets
iTeos Therapeutics cash flows

iTeos Therapeutics dividend policy

The company doesn't provide dividend.

iTeos Therapeutics shares

TickerNameTypeNominal valueISINPrice
ITOS:USiTeos TherapeuticsCommon share-US46565G1040$17.48
iTeos Therapeutics news
13.05.2022
iTeos Therapeutics' GAAP net income for 3 months of 2022 was $69.582 million, compared to a loss of $13.534 million in the previous year. Revenues were $152.522 million. The company did not generate revenues a year earlier.
Source: {source} pictogram investors.iteostherapeutics.com
Pictogram next
24.03.2022
iTeos Therapeutics' GAAP net income for 2021 was $214.521 million, compared to a loss of $38.033 million in the previous year. Revenue was $344.775 million. The company did not generate revenue a year earlier.
Source: {source} pictogram investors.iteostherapeutics.com
Pictogram next
11.11.2021
iTeos Therapeutics' GAAP net income for 9M 2021 was $29.649 million, compared to a loss of $23.129 million in the previous year. Revenues were $104.271 million. The company did not generate revenues a year earlier.
Source: {source} pictogram investors.iteostherapeutics.com
Pictogram next
12.08.2021
iTeos Therapeutics' GAAP loss for 6M 2021 was $39.993 million, up 3.2 times from $12.449 million in the previous year.
Source: {source} pictogram investors.iteostherapeutics.com
Pictogram next
All iTeos Therapeutics news
General information
Company nameiTeos Therapeutics
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address139 MAIN STREET CAMBRIDGE MA 02142 857-204-4583
Mailing address139 MAIN STREET CAMBRIDGE MA 02142
Websiteinvestors.iteostherapeutics.com
Information disclosurewww.sec.gov